Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DCPH

DCPH - Deciphera Pharmaceuticals Inc Stock Price, Fair Value and News

$25.59 
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

DCPH Price Action

DCPH RSI Chart

DCPH Valuation

DCPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DCPH Fundamentals

DCPH Revenue

DCPH Earnings

DCPH Profitability

DCPH Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024174.9M000
2023138.3M144.1M151.4M163.4M
2022100.2M109.1M121.9M134.0M
202167.2M83.7M91.4M96.1M
2020030.7M36.4M42.1M
201900025.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Deciphera Pharmaceuticals Inc

DCPH
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEdeciphera.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES300